Ask about this productRelated genes to: LTB4R Blocking Peptide
- Gene:
- LTB4R NIH gene
- Name:
- leukotriene B4 receptor
- Previous symbol:
- P2RY7, GPR16, CMKRL1
- Synonyms:
- BLTR, P2Y7, LTB4R1
- Chromosome:
- 14q12
- Locus Type:
- gene with protein product
- Date approved:
- 1998-09-25
- Date modifiied:
- 2016-10-05
Related products to: LTB4R Blocking Peptide
Related articles to: LTB4R Blocking Peptide
- Ochratoxin A (OTA), a prevalent food contaminant, is closely linked to the development of various cancers, including clear cell renal cell carcinoma (ccRCC). However, the potential mechanisms remain to be explored. In this study, we employed network toxicology, machine learning, and molecular docking techniques to systematically investigate the potential molecular mechanisms underlying OTA-associated ccRCC. We normalized transcriptional data from two Gene Expression Omnibus (GEO) datasets and analyzed it using differential expression analysis and weighted gene co-expression network analysis (WGCNA), identifying 3224 ccRCC-associated target genes. These were intersected with 232 predicted OTA target genes, yielding a total of 56 overlapping targets. The results of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses indicated that these targets were primarily enriched in critical biological processes, including extracellular matrix remodeling, immune microenvironment regulation, signaling pathway transduction, cellular metabolism, and protein homeostasis. Machine learning analysis identified "glmBoost + RF" (a sequential combination of feature selection and classifier) as the optimal model, from which nine key genes were extracted. SHapley Additive exPlanations (SHAP) analysis revealed five core genes (, , , , ), with and serving as the principal driver genes of the model. Validation of the model's diagnostic efficacy and single-cell transcriptome analysis indicated that the core genes exhibited significant differential expression patterns, cell-type-specific expression characteristics, and high independent diagnostic efficacy. Molecular docking analyses predicted stable interactions between OTA and the core target proteins. These findings suggest potential molecular links between OTA exposure and ccRCC, providing a foundation for hypothesis generation and future experimental validation. - Source: PubMed
Publication date: 2026/03/25
Huang ChenjieWei LuluYuan WenqiLu YaohongYan ZiyouZhang Gedi - Colorectal cancer (CRC) is a prevalent malignant tumour, with its incidence and mortality rates consistently ranking among the highest and exhibiting an upward trend. Extensive screening and early diagnosis are crucial for managing CRC progression and improving patient prognosis. This study aims to construct a novel analytical framework for integrating the sequencing data from tumour tissue and peripheral blood. By integrating and analysing the multi-omics data and clinical data from tumour tissues and peripheral blood, we confirmed that the gene is significantly upregulated not only in tumour tissues but also in the peripheral blood of CRC patients. Further single-cell RNA sequencing (scRNA-seq) and immune cell correlation analyses revealed that () is primarily expressed in macrophages, T cells, and other immune cells, with a significant negative correlation observed with M1-type macrophages, suggesting its potential pro-tumourigenic role in CRC by suppressing M1 macrophage. Additionally, simulated gene knockout analysis (scTenifoldKnk) demonstrated that knockout significantly impacts immune-related pathways, including immune response and immune receptor activity. These findings not only highlight the potential of as a peripheral blood diagnostic marker for CRC but also elucidate its involvement in tumour progression, offering novel insights for early clinical diagnosis and tumour screening systems. - Source: PubMed
Publication date: 2026/03/11
Wang TongLi ChangqingWang Zongkui - Blood-based biomarkers that capture systemic immunity could complement tissue-based assays for prognostication in advanced gastric cancer receiving programmed cell death protein 1 (PD-1)-based chemoimmunotherapy. We evaluated whether baseline plasma immune proteomics can stratify clinical outcomes and be operationalized into a clinically usable model. - Source: PubMed
Publication date: 2026/01/12
Zhan ZhouweiLin RuyuChen YiguiHuang ShaLin LupingZheng HanchenWang XiaojieLin XiaoyanGuo ZengqingHu QiaotingChen Bijuan - Leukotriene B (LTB), a potent chemotactic and immune-modulating eicosanoid, signals via two receptors (BLT and BLT), leading to rapid but transient migratory, adhesive and secretory responses in phagocytes. Previously, we reported that BLT is the predominating BLT in human umbilical vein endothelial cells (HUVEC). However, little is known about how ligation of these receptors affects adhesive and secretory endothelial responses over time. Here, we demonstrate that in HUVEC, LTB dose-dependently and stereospecifically causes a biphasic tethering of neutrophils, where the second phase is robust, similar to that induced by lipopolysaccharide, and persists for 3-8 h. LTB also causes up-regulation of E-selectin, ICAM-1 and VCAM-1 and release of MCP-1 and nitric oxide (but not of IL-8 or HMGB1). These responses appeared to be mediated via BLT and BLT as judged by BLT shRNA gene silencing and/or treatment with BLT and BLT specific antagonists prior to LTB activation of HUVEC. Moreover, LTB responses used primarily the MAP kinase/Erk pathway. Our findings suggest a new role for LTB not only in early but also in late vascular inflammatory responses. - Source: PubMed
Johansson Anne-SofieHaeggström Jesper ZPalmblad Jan - Monoclonal antibodies (mAbs) targeting cell-surface molecules are pivotal in biomedical research, diagnostic applications, and biotechnology. Over the past four decades, the CD nomenclature system, established by the Human Leukocyte Differentiation Antigens Workshops and endorsed by the International Union of Immunological Societies (IUIS), has provided a standardized naming convention for both mAbs and the cell surface molecules they target. G protein-coupled receptors (GPCRs) represent the largest family of cell-surface receptors, playing essential roles in both innate and adaptive immune responses. Despite their significance, GPCRs are underrepresented in terms of well-validated mAbs available for flow cytometry and therapeutic applications. At the Eleventh HLDA Workshop (HLDA11), new CD nomenclature has been assigned to thirteen GPCR cell-surface molecules expressed on immune cells: CD198 (CCR8), CD199 (CCR9), CD372 (CCR10), CD373 (CX3CR1), CD374 (XCR1), CD375 (GPR15), CDw376 (GPR26), CD377 (SSTR3), CD378 (C3AR1), CDw379 (FPR2), CD380 (LTB4R), CDw381 (GPR183), and CDw382 (F2RL1). In this article, we introduce the newly established CD nomenclature for mAbs targeting the GPCR family. We detail the quantitative expression profiles of these molecules on various subsets of leukocytes and provide validation data for these mAbs. The implications of these expression profiles are discussed for the potential therapeutic targeting of immune-mediated diseases and cancer. - Source: PubMed
Fernández-Calles JavierKužílková DanielaHedin FannyBakardjieva-Mihaylova VioletaŠkvárová Kramarzová Karolinavan Zelm Menno CCosma AntonioKalina TomasEngel Pablo